Enhancement of Oral Bioavailability of Ibandronate Through Gastroretentive Raft Forming Drug Delivery System: In Vitro and In Vivo Evaluation
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 4847-4858
Abstract
Background: Bisphosphonates have very low bioavailability and cause irritation of the esophagus and stomach. This study was planned to improve the oral bioavailability of ibandronate through the formation of a raft in the stomach. Bisphosphonate-induced irritation of the esophagus and stomach is prevented by the formation of a raft. Materials and Methods: The nanostructured raft was developed through the use of nanosized citrus pectin (NCP). The particle size of NCP was measured by zeta sizer and SEM. The percentage of NCP and the neutralization profile of raft was studied. The ibandronate, polymers, and the developed formulation were characterized by FTIR, XRD, TGA, and DSC. The release of ibandronate was studied in 0.1 N HCl, 0.5 N HCl, 1 N HCl, and simulated gastric fluid (SGF) and a cell viability study was performed using Caco-2 cells. The PPR5 formulation and Bonish 150 mg tablets were selected as test and reference formulations, respectively, for pharmacokinetic study. Twelve healthy albino rats were taken and divided into two groups using a Latin square crossover design, and the blood samples were collected for 24 hours. Results: The SEM image showed that the particle size of NCP was 159 nm. The raft of PPR5 showed 94% NCP and 45 minutes duration of neutralization. The FTIR and XRD showed chemical stability and a uniform distribution of ibandronate in the raft. The TGA and DSC indicated the thermal stability of formulation. The release of 99.87% ibandronate at 20 minutes was observed in the SGF. The values of Cmax for the reference and test formulations were 493± 0.237 ng/mL and 653± 0.097 ng/mL, respectively. The AUC(0-t) of the reference and test formulations was 3708.25± 3.418 ng/mL.h and 6899.25± 3.467 ng/mL.h, respectively. Conclusion: The NCP has been successfully prepared from citrus pectin and has shown effective porous raft formation. The bioavailability of the ibandronate from newly developed PPR5 was higher than the already marketed formulation.Keywords
This publication has 26 references indexed in Scilit:
- A comparative study on the raft chemical properties of various alginate antacid raft-forming productsDrug Development and Industrial Pharmacy, 2017
- pH‐responsive alginate–pectin polymeric rafts and their characterizationAdvances in Polymer Technology, 2017
- pH‐Sensitive pectin polymeric rafts for controlled‐release delivery of pantoprazole sodium sesquihydrateJournal of Applied Polymer Science, 2016
- pH responsive alginate polymeric rafts for controlled drug release by using box behnken response surface designDesigned Monomers and Polymers, 2016
- Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritationInternational Journal of Biological Macromolecules, 2014
- Impact of salt form and molecular weight of chitosan on swelling and drug release from chitosan matrix tabletsCarbohydrate Polymers, 2013
- Application of pectin in oral drug deliveryExpert Opinion on Drug Delivery, 2011
- Controlled release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parametersInternational Journal of Pharmaceutics, 2006
- Change in Particle Size of Pectin Reacted with Pectinesterase Isozymes from Pea (Pisum sativum L.) SproutJournal of Agricultural and Food Chemistry, 2001
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996